To include your compound in the COVID-19 Resource Center, submit it here.

Philogen bypasses VCs, taps Italian syndicate for €62M to fuel late stage cancer programs

With €62 million ($69.6 million) in series A cash to carry its two late-stage candidates through clinical development, Philogen will soon have to decide whether to rely on additional deals to find commercialization partners, or establish its own sales force.

The funds will push the company's two lead candidates through to registration, Philogen S.p.A. (Siena, Italy) co-founder Dario Neri told BioCentury. Both

Read the full 610 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers